DONATE TODAY
To Increase Patient Access
End Brain Cancer Mobile App to download your number one tool for navigating this disease.

March 10, 2024

Understanding Syndromes Associated with CNS Tumors

Brain tumors are complex conditions influenced by our genes. Recent breakthroughs have revealed several genetic syndromes that increase the likelihood of developing these tumors, whether passed down through families or occurring randomly.

These syndromes, each linked to specific genetic changes, heighten the risk of central nervous system (CNS) tumors. For example, Von Hippel-Lindau disease and Tuberous sclerosis stem from mutations in certain genes, leading to tumor growth in the brain and other organs.

Li-Fraumeni syndrome, Turcot syndrome, and Neurofibromatosis type 1 and 2 are other conditions that can make someone more prone to brain tumors due to genetic mutations. And it's not just these syndromes—Lynch syndrome, known for its link to colorectal cancer, also increases the risk of CNS tumors.

Genetic testing is crucial in identifying these risks. Genetic counselors play a vital role, helping families understand their genetic makeup and providing options for testing. By knowing their risks, patients and families can take steps to manage their health proactively.

As our understanding of genetics grows, ongoing research will continue to uncover more about how these syndromes contribute to brain tumor development. By integrating genetic testing and counseling into healthcare, we can empower patients to navigate their genetic risks and take control of their health journey.

If you or a family member are interested in learning more about Genetic Testing, please feel free to get in touch with Shreya Prakash by emailing her at shreya@endbraincancer.org or calling/texting 425-436-8688. Alternatively, you can complete our Patient Interest Form, and End Brain Cancer Initiative (EBCI) will contact you.

ENDBRAINCANCER INITIATIVE | CHRIS ELLIOTT FUND

Enhancing patient outcomes by expanding FDA-approved treatment modalities and fueling research in the pharma/bio/life sciences, device & diagnostic industries and by closing the existing GAP from initial diagnosis to IMMEDIATE AND EXPANDED ACCESS to specialists, researchers, advanced & innovative treatments, clinical trials and critical care with the ultimate goal of improving patient outcomes through updating and improving WHO & NCCN Guidelines and clinical practices related to Standard of Care for brain cancer patients.

TAX ID:26-2185614
DONATE
corporate partners
upcoming events
resources
About us
envelopephonemap-markerpointer-right
linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram